Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Circulating tumor cells (CTC) and KRAS mutant circulating free DNA (cfDNA) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer

Fig. 2

KRAS mutation detection in plasma cfDNA in PDAC cases. a. G12D KRAS mutation detection in plasma and genomic DNA by QX200™ Droplet Digital™ PCR. b. Frequency of mutant KRAS detection in plasma in PDAC. c. Correlation of cfDNA concentration and mutant KRAS detection. *DNA concentration was estimated by the number of copies of the RNaseP gene in 20 μl of cfDNA in plasma. d. Kaplan Meier survival analysis of KRAS mutation status in plasma cfDNA

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us